Larimar Therapeutics (LRMR) Change in Accured Expenses (2013 - 2025)

Larimar Therapeutics (LRMR) has reported Change in Accured Expenses for 13 consecutive years, with $25.8 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Change in Accured Expenses rose 252.91% year-over-year to $25.8 million; the trailing twelve-month figure through Dec 2025 stood at $37.6 million (up 179.49% YoY), and the FY2025 full-year result was $37.6 million, up 179.49% from the prior year.
• Change in Accured Expenses advanced to $25.8 million in Q4 2025 per LRMR's latest filing, from $11.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $25.8 million in Q4 2025 and bottomed at -$3.6 million in Q3 2024.
• Historically, Change in Accured Expenses has averaged $2.6 million across 5 years, with a median of $924500.0 in 2022.
• The widest YoY moves for Change in Accured Expenses: up 747.18% in 2021, down 635.65% in 2021.
• Over 5 years, Change in Accured Expenses stood at -$1.4 million in 2021, then soared by 152.33% to $719000.0 in 2022, then jumped by 218.78% to $2.3 million in 2023, then jumped by 218.46% to $7.3 million in 2024, then soared by 252.91% to $25.8 million in 2025.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $25.8 million, $11.3 million, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.